220991-32-2

Basic information

• Product Name: Robenacoxib
• Synonyms: Robenacoxib;5-Ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]benzeneacetic acid;CGS 34975;Onsior
• CAS NO: 220991-32-2
• Molecular Formula: C16H13F4NO2
• Molecular Weight: 327.2735328
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 220991-32-2.mol

Chemical Properties

• Boiling Point: 350.1°Cat760mmHg
• Flash Point: 165.5°C
• Appearance: /
• Density: 1.407g/cm³
• Vapor Pressure: 1.69E-05mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.16±0.10(Predicted)
• CAS DataBase Reference: Robenacoxib(CAS DataBase Reference)
• NIST Chemistry Reference: Robenacoxib(220991-32-2)
• EPA Substance Registry System: Robenacoxib(220991-32-2)

Safety Data

• Hazardous Substances Data: 220991-32-2(Hazardous Substances Data)

Usage

Uses

Used in Veterinary Medicine:
Robenacoxib is used as a nonsteroidal analgesic, anti-inflammatory, and antipyretic agent for the treatment of pain and inflammation in cats and dogs. Its COX-2 selective inhibition property allows for effective management of these conditions without causing significant side effects commonly associated with non-selective COX inhibitors.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Robenacoxib is utilized as a novel COX-2 selective inhibitor. Its selective action on COX-2 makes it a valuable compound for the development of new drugs targeting inflammation and pain, with potentially fewer side effects compared to non-selective COX inhibitors.
Chemical Properties:
Robenacoxib is a white solid, which contributes to its stability and ease of formulation in various dosage forms for veterinary use.

InChI:InChI=1/C16H13F4NO2/c1-2-8-3-4-12(9(5-8)6-13(22)23)21-16-14(19)10(17)7-11(18)15(16)20/h3-5,7,21H,2,6H2,1H3,(H,22,23)

Upstream product

• 769-39-1 2,3,5,6-tetraflourophenol 
• 20172-36-5 α-chloro-N-(p-ethylphenyl)acetamide 
• 59-48-3 2-oxoindole 
• 64483-69-8 5-acetylindolin-2-one 
• 220991-61-7 N-(2’3’5’6’-tetrafluorophenyl)-5-ethylindol-2-one 

Relevant articles and documents

Preparation method of robencoxib intermediate

The invention relates to a preparation method of a robencoxib intermediate, and belongs to the technical field of pharmacy. The preparation method disclosed by the invention comprises the following step of: reacting a compound R1-RBC04 in the presence of

Preparation method of robecoxib

The invention relates to a preparation method of robecoxib. The preparation method comprises the following steps: under the protection of inert gas, adding 5-ethylindole-2-ketone, 2, 3, 5, 6-tetrafluoroiodobenzene, a catalyst, alkali, a ligand and a solve

Method for preparing acid

The invention relates to a method for preparing an acid, and belongs to the technical field of pharmacy. The method comprises: carrying out a reaction on a reaction material and an alkali in an organic solvent, making the reaction product contact hydrazin

Method for preparing robenacoxib

The invention belongs to the technical field of production of non-steroidal anti-inflammatory drugs and relates to a method for preparing robenacoxib. The method specifically comprises the following steps: (1) in the presence of nitrogen, adding a solvent

Removal of heavy metals from organic reaction mixtures: Preparation and application of functionalized resins

Using a toolbox, sulfur and amine ligands are attached to a variety of hydrophobic and hydrophilic resins, and the combinations were tested for the removal of heavy metals from a number of products, prepared by metal-catalyzed reactions. As a result, cheap combinations of silica resins and simple polyamines proved to be among the most effective metal scavengers particularly in apolar solvents such as cyclohexane. Expensive cyclic polyamines are not suitable, owing to kinetic retardation of complexation. Functionalized PEGbased polymers, originally designed for solid phase synthesis, show promising performance as metal scavengers. The results are discussed and compared to alternative approaches for purification such as salt-formation and chemical downstream transformation.

Method for the treatment and prevention of cachexia

Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.

Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1is chloro or fluoro; R2is hydrogen or fluoro; R3is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4is hydrogen or fluoro; and R5is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.